RT Journal Article
T1 Transcriptomic mapping of non-small cell lung cancer K-RAS p.G12C mutated tumors: identification of surfaceome targets and immunologic morrelates
A1 Alcaraz Sanabria, Ana
A1 Cabañas Morafraile, Esther
A1 Fernández Hinojal, Gonzalo
A1 Velasco Díez, Guillermo
A1 Pérez Segura, Pedro
A1 Pandiella, Atanasio
A1 Györffy, Balázs
A1 Ocaña, Alberto
AB Targeting K-RAS-mutant non-small cell lung cancer (NSCLC) with novel inhibitors has shown promising results with the recent approval of sotorasib in this indication. However, progression to this agent is expected, as it has previously been observed with other inhibitors. Recently, new immune therapeutics, including vectorized compounds with antibodies or modulators of the host immune response, have demonstrated clinical activity. By interrogating massive datasets, including TCGA, we identified genes that code for surface membrane proteins that are selectively expressed in K-RAS mutated NSCLC and that could be used to vectorize novel therapies. Two genes, CLDN10 and TMPRSS6, were selected for their clear differentiation. In addition, we discovered immunologic correlates of outcome that were clearly de-regulated in this particular tumor type and we matched them with immune cell populations. In conclusion, our article describes membrane proteins and immunologic correlates that could be used to better select and optimize current therapies.
PB Frontiers Media
SN 1664-3224
YR 2022
FD 2022-02
LK https://hdl.handle.net/20.500.14352/71804
UL https://hdl.handle.net/20.500.14352/71804
LA eng
NO Ministerio de Economía y Competitividad (MINECO)/FEDER
NO Ministerio de Ciencia e Innovación (MICINN)
NO Instituto de Salud Carlos III (ISCIII)
NO Junta de Comunidades de Castilla-La Mancha
NO National Research, Development and Innovation Office (Hungary)
NO CRIS Cancer Foundation
DS Docta Complutense
RD 8 abr 2025